Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD66 expression in acute leukaemia.

M Carrasco1, L Muñoz, M Bellido

  • 1Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Annals of Hematology
|July 20, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis.

Cancer reports (Hoboken, N.J.)·2025
Same author

Evaluation of microplastics and metal accumulation in domestic ducks (Anas platyrhynchos f. domesticus) of a contaminated reservoir in Central Mexico.

Marine pollution bulletin·2025
Same author

A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2022
Same author

Assessment of Confirmed Clinical Hypersensitivity to Rituximab in Patients Affected with B-Cell Neoplasia.

Advances in hematology·2020
Same author

Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies).

Annals of hematology·2020
Same author

Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature.

Bone marrow transplantation·2019

CD66 expression is significantly more common in acute lymphocytic leukemia (ALL) than acute myeloblastic leukemia (AML). Aberrant CD66 expression may aid in detecting minimal residual disease (MRD) in ALL patients.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • CD66 antigens belong to the carcinoembryonic antigen (CEA) family within the immunoglobulin gene superfamily.
  • While typically found on myeloid or monocytic cells, CD66 expression has been observed in B-cell lineage acute lymphocytic leukemia (ALL) blasts.
  • Understanding CD66 expression patterns can offer insights into leukemia subtypes and progression.

Purpose of the Study:

  • To analyze the expression of CD66 in patients with acute leukemia.
  • To determine the frequency of CD66 expression in acute myeloid leukemia (AML) and B-cell lineage ALL.
  • To investigate the potential of CD66 as a marker for minimal residual disease (MRD) in ALL.

Main Methods:

  • Analysis of antigenic expression using triple combinations of monoclonal antibodies (mAbs).

Related Experiment Videos

  • Patient cohort included 45 individuals with various forms of acute leukemia.
  • CD66 expression was quantified and correlated with other myeloid and B-cell markers.

    • Main Results:

    • CD66 expression was detected in 6.8% of AML patients and 66.7% of B-cell lineage ALL patients (P<0.001).
    • In chronic myelocytic leukemia (CML) blast crisis (BC), CD66 was present in lymphoid BC but absent in myeloid BC.
    • CD66 co-expression with myeloid antigens (CD13, CD33, CD117) was noted in CD66+ ALL/Ly-BC cases.
    • In complete remission, CD66 expression correlated with abnormal B-cell differentiation and increased CD34/CD19+ cells in most MRD cases.

    Conclusions:

    • CD66 expression is significantly more prevalent in B-cell lineage ALL than in AML.
    • Aberrant CD66 expression shows promise as a marker for investigating minimal residual disease (MRD) in ALL.
    • Further research is needed to explore the association between CD66 reactivity and bcr-abl in adult ALL.